

Are Alopecias Non-Communicable Degenerative Diseases?

Paul Clayton*

Department of Personal and Preventive Medicine, Institute of Interdisciplinary Medicine, Moscow, Russia

ABSTRACT

The incidence of androgenic and areata alopecia appears to be increasing in some areas. While genetic factors have been identified, the relatively low level of heritability indicates the importance of external and epigenetic factors. Many of these are included in or driven by dietary shift, which thereby impacts on multiple aspects of the hair follicle environment. Various potential pharmaconutritional interventions are outlined.

Keywords: Endocrine; Hair loss; Epidemiology; Alopecia areata

INTRODUCTION

While the global epidemiology of hair loss is not well documented, there is evidence that the overall incidence may be rising in some regions, likely due to average earlier onset and partly linked to endocrine and immunological issues. This mini-review focuses on primarily on androgenic alopecia and female pattern hair loss, with reference also to alopecia areata, and sets them in the context of dietary shift and lifestyle changes.

LITERATURE REVIEW

In 1998 a community-based study in the USA found Male Pattern Hair Loss (MPHL) affecting 42% of the male population, ranging from 16% of males aged 18-29 to 53% of males aged 40-49 [1]. A 2000 Norwegian community study of males aged 25-50 reported 63% with hair loss, a quarter of whom reported moderate to severe loss [2]. In 2010, a large China community study found MPHL in 21.3% of males aged 18-59, a figure significantly lower than Caucasians and similar to Koreans at that time [3]. Since that time hair loss of all types is reported to have increased in China [4-6], as it has in South Korea [7-9], in both cases particularly affecting younger adults. In South Korea the growing problem of hair loss in young adults has even recently become an election issue [10].

A 2018 Chinese survey of male and female university students aged 18-24 recorded slightly over 60% with some degree of hair loss [4-6], and a 2015 Turkish study of alopecia in high school students aged 12-18 reported incidence of hair thinning in 37% [11]. If the reports of earlier onset and increased incidence are

substantiated, a number of variables might be considered as potential contributory factors.

1. The incidence of autoimmune diseases has increased [12], several of which are associated with a higher risk of developing alopecia areata [13-15].
2. While PCOS is linked to hirsutism of the face and chest and to acanthosis nigricans, it also increases the risk of female pattern hair loss and androgenic alopecia [16]. The increasing incidence of PCOS among females in some regions may therefore be contributing to overall alopecia figures [17].
3. Average age of puberty has fallen in both sexes [18,19], which would be expected to advance the onset of androgenic alopecia.
4. Exposure to endocrine-disrupting chemicals (EDC's) has increased [20]. There appears to be a relationship between EDC exposure and advanced age of puberty, but it is a highly complex one [21,22]; the effects are gender- and compound-specific, and depend on the exposure window.
5. There may also be a link between EDC exposure and PCOS. EDC's bind to and alter hormone receptors including estrogen, progesterone, androgen, and glucocorticoid receptors [23,24]; and there is evidence that pre-natal exposure may predispose to PCOS in later life [25].
6. EDC's are routinely found in hair and urine samples, even in children [20]; and occur in a significant number of hair products [26], which deliver high concentrations of these compounds directly to the scalp. There may therefore be localized as well as systemic effects [27].

Correspondence to: Paul Clayton, Department of Personal and Preventive Medicine, Institute of Interdisciplinary Medicine, Moscow, Russia, Tel: +44-800-644-0322; E-mail: paulrclayton@gmail.com

Received: 22-Aug-2022, Manuscript No. HTT-22-18966; **Editor assigned:** 25-Aug-2022, PreQC No: HTT-22-18966 (PQ); **Reviewed:** 09-Sep-2022, QC No: HTT-22-18966; **Revised:** 15-Sep-2022, Manuscript No: HTT-22-18966 (R). **Published:** 23-Sep-2022; DOI: 10.35248/2167-0951.22.12.192

Citation: Clayton P (2022) Are Alopecias Non-Communicable Degenerative Diseases? Hair Ther Trasplant. 12: 192.

Copyright: © 2022 Clayton P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

7. Chronic low-grade inflammation is thought to be involved in hair loss in both sexes [28-34], and is likely exacerbated by recent dietary shifts which have shifted the balance of anti-and pro-inflammatory dietary factors in favour of the latter [35-38].
8. Falling intakes and/or reduced bio-functionality of iodine [39,40], and selenium [41-43], have likely contributed to rising rates of hypothyroidism [44,45], which is linked to FPHL via telogen effluvium.
9. Diabetes and its metabolic constituents have been linked to increased central scalp hair loss in women [46,47], and to androgenic alopecia [48-51]. The remarkable increase in NIDDM may therefore be another driver of alopecia.
10. Significant phenotypical (hair volume) differences between monozygotic male twins with androgenic alopecia [52], indicate a role for external [53], and epigenetic [54], factors involving histone modification [55,56].
11. Histone methylation and acetylation rates are affected by the availability of dietary methyl groups and intakes of prebiotic fiber respectively, and by ancillary dietary compounds including isothiocyanates, polyphenols, carotenoids, omega 3 HUFA's, vitamin D and others which impact mRNA expression [57].
12. Post-transitional dietary shift from basic produce to ultra-processed foods has reduced dietary intakes of all the above compounds; the phytonutrient density of ultra-processed foods is reduced by inter alia dilution with sugars, other simple carbohydrates and plant oils [58].

DISCUSSION

Current treatments

The limitations and adverse effects of the two pharmaceutical staples, minoxidil and finasteride, are well known and need not be repeated here. The most recent oral treatment for alopecia areata Olumiant (baricitinib), a JAK inhibitor originally designated for the treatment of RA, comes with a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. While these adverse effects may be a reasonable trade-off against a painful and crippling disorder such as severe RA, they seem excessive in the context of hair loss.

Nutritional remedies for hair loss include various B vitamins, vitamin D, trace elements, amino acids, garlic gel, marine proteins, capsaicin, melatonin and onion juice. All have some evidential support, albeit weak [59], but the vitamins, trace elements and amino acids presumably only rectify deficiency states. Herbal remedies with some evidence include *Curcuma aeruginosa*, *Trifolium pratense*, *Panax ginseng* and *Serenoa repens*. All of these are thought to act primarily via the inhibition of 5 α -reductase [60], with all the limitations that this mechanism entails.

Future developments

PGD2: Recent research underpins the role of PGD2 and its receptors GPR44 and PTGDR in alopecia. PGD2, a pro-

inflammatory mediator [61], increases hair loss in mice [62], is elevated in bald areas of the scalp in males with androgenic alopecia, and reduces anagenic hair lengthening [62]. The selective GPR44 receptor antagonist Septiprant was relatively ineffective as an anti-inflammatory agent in seasonal allergic rhinitis [63], and failed as a hair loss treatment [64]. However, an extract of *Leea indica* leaves with PGD2 synthase inhibitory activity showed enhanced hair growth in a pre-clinical model [65]. HairAgeVitae, an alkaloid-free extract of *Ageratum conyzoides* which blocks 5-alpha reductase and also inhibits PGD2 synthesis, generated positive results in males and females in two clinical trials [66,67], the second of which was reasonably robust.

Dysbiosis: Colonic dysbiosis plays a crucial role in many disease states, both within the gut and in almost all other tissues, to the extent that a fibre-depleted diet is associated with a 30% increased risk of early death [68]. Colonic and dermal dysbiosis alter systemic and local immune responses, and are suspected of promoting the development of skin diseases including atopic dermatitis, psoriasis, acne vulgaris, dandruff and skin cancer [69,70]. In some cases the mechanism linking colonic dysbiosis and hair loss is relatively well characterized. Colonic dysbiosis characterized by overgrowth of *Lactobacillus murinus* reduces biotin in the gut of mice, and causes alopecia [71]. Biotin deficiency causes alopecia in pre-clinical models [69], and humans [72], giving these findings coherency. Rectifying (human) colonic dysbiosis with blended prebiotics, which can improve biotin status [73] and at the same time exert systemic anti-inflammatory effects [74], may therefore provide some efficacy against hair loss. The dermal microbial population is also significant, and estimated at 10 to the 12th [59], is also significant; and dermal dysbiosis is emerging as another key variable involved in alopecia. The hair follicle environment contains stem cells, immune cells and a population of bacteria, fungi and bacteriophages, and the bulb and bulb regions are immune-privileged [75,76]. A healthy microbial profile in the follicle plays a role in setting appropriately low (physiological) levels of inflammatory stress, involved in homeostasis and innate immune defense [77,78]. Higher levels of pathogenic taxa in the hair follicle can disrupt local immune-privilege [79], contributing to a pro-inflammatory state in the scalp [79,80], which can damage or destroy the follicle [81]. These taxa are linked to alopecia areata [82,83], and there is evidence of an excessively inflammatory component in androgenic alopecia also [84,85]. Colonic dysbiosis, dermal dysbiosis and follicular health appear to be inter-linked. There is some evidence that colonic dysbiosis may, partly by inducing gastrointestinal and then systemic inflammation and also possibly *via* more direct gut-dermis connections, increase inflammatory stress in the hair follicle and damage hair growth [86-89]. Specific colonic species such as *Clostridium difficile* [87], and dermal species *Malassezia* [88] and *C. acnes* [89] have been implicated. Given their shared embryological origins, the structural/functional similarity of gut and skin and hand-mouth-skin microbial transfer, the possibility of a more direct relationship between colonic and dermal microbiota cannot be excluded [90,91]. This may provide another rationale for utilizing prebiotic fibers to re-establish a pre-transitional colonic microbiota.

Glycemic control: Diabetes and its metabolic components have been linked to an increased incidence of hair loss [46-51]. More recently, Type 2 diabetes was associated with significantly increased central-scalp hair loss in women [47], an association which was unaffected by diabetic treatment. Diabetes causes chronic inflammatory stress [92], immune dysfunction [93], and altered skin pH [94], providing several possible mechanistic links to alopecia. Here again, the role of prebiotic fibers in supporting glycemic control [95], may be relevant. Given the established use of non-medical tools (i.e., reduced intakes of digestible carbohydrate, increased levels of physical activity, weight loss) in improving and reversing Type 2 diabetes [96-101], with resulting normalisation of cardiovascular, metabolic and hepatic parameters [102,103], it is conceivable that these lifestyle strategies may impact positively on hair growth also.

Inflammatory stress: Dietary shift involving a move away from basic produce toward increasing consumption of ultra-processed foods [104-106], is associated with rising rates of most if not all of the non-communicable chronic degenerative diseases [107-112]. This shift has reduced intakes of key anti-inflammatory nutrients such as the polyphenols, omega 3 HUFA's and prebiotic fibers, contributing to wide-spread chronic inflammation [113,114] and to a situation where poor diet has become the leading cause of death world-wide from diseases with inflammatory components [115].

This excessively inflammatory background has been shown to impact adversely on immune-privileged processes in males and females [116,117], and it is reasonable to assume that similar effects may be present in the hair follicle also. This would be expected to increase the tendency to anagenic curtailment, androgenic alopecia and alopecia areata [118-123].

CONCLUSION

Alopecia has likely always been with us, as shown by the fact that various non-human primates may present with alopecia, and genome-wide association studies which have identified susceptibility loci accounting for roughly two fifths of the heritability of androgenic alopecia. However, a number of factors associated with the modern diet and lifestyle may be contributing to an increased incidence of androgenic alopecia and alopecia areata over and above the genetically disposed. This is hinted at in recent research. By inducing chronic inflammatory stress, dysbiosis, and metabolic and epigenetic disruption, the modern diet and lifestyle increase the incidence of many non-communicable degenerative conditions; and it may be useful to consider the alopecias within this context. A restoration of pre-transitional nutritional and therefore metabolic and epigenetic profiles will likely reduce the numbers of non-genetically determined cases.

CONFLICT OF INTEREST

The author has consulted with GenCor Pacific, the company which developed a standardized alkaloid-free extract of *Ageratum conyzoides*.

REFERENCES

- Rhodes T, Girman CJ, Savin RC, Kaufman KD, Guo S, Lilly FR, et al. Prevalence of male pattern hair loss in 18-49 year old men. *Dermatol Surg.* 1998; 24: 1330-1332.
- DeMuro-Mercon C, Rhodes T, Girman CJ, Vatten L. Male-pattern hair loss in Norwegian men: a community-based study. *Dermatology.* 2000; 200: 219-222.
- Wang TL, Zhou C, Shen YW, Wang XY, Ding XL, Tian S, et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. *Br J Dermatol.* 2010; 162: 843-847.
- Zhihua L. Young Chinese troubled by hair loss. *China Daily.* 2019.
- Chen S. Chinese people losing their hair earlier than ever before, research shows. *South China Morning Post.* 2018.
- Xiaonan W. The epidemic of hair loss for Chinese millennials. *CGTN.* 2019.
- Lee JH, Kim HJ, Han KD, Han JH, Bang CH, Park YM, et al. Incidence and prevalence of alopecia areata according to subtype: a nationwide, population-based study in South Korea (2006-2015). *Br J Dermatol.* 2019; 181: 1092-1093.
- Soh BW, Kim SM, Kim YC, Choi GS, Choi JW. Increasing prevalence of alopecia areata in South Korea. *J Dermatol.* 2019; 46: e331-e332.
- Young Koreans losing hair, tonics, pills and tinctures fly off shelves. *Korea JoongAng Daily.* 2021.
- Min-sik Y. [Newsmaker] Should politicians care about your hair loss?. 2022
- Ozay O, Arslantas D, Unsal A, Bulur I. The frequency of alopecia and quality of life in high-school students in rural areas (Sivrihisar, Mahmudiye, Alpu, and Beylikova) of Eskisehir. *North Clin Istanbul.* 2019; 6: 226-235.
- Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, et al. Increasing prevalence of antinuclear antibodies in the United States. *Arthritis Rheumatol.* 2020; 72: 1026-1035.
- Brenner W, Diem E, Gschnait F. Coincidence of vitiligo, alopecia areata, onychodystrophy, localized scleroderma and lichen planus. *Dermatologica.* 1979; 159: 356-360.
- Muller SA, Winkelmann RK. Alopecia areata. An evaluation of 736 patients. *Arch Dermatol.* 1963; 88: 290-297.
- Thomas EA, Kadyan RS. Alopecia areata and autoimmunity: a clinical study. *Indian J Dermatol.* 2008; 53: 70-74.
- Prasad S, De Souza B, Burns LJ, Lippincott M, Senna MM. Polycystic ovary syndrome in patients with hair thinning. *J Am Acad Dermatol.* 2020; 83: 260-261.
- Miazgowski T, Martopullo I, Widecka J, Miazgowski B, Brodowska A. National and regional trends in the prevalence of polycystic ovary syndrome since 1990 within Europe: the modeled estimates from the Global Burden of Disease Study 2016. *Arch Med Sci.* 2019; 17: 343-351.
- Herman-Giddens ME, Steffes J, Harris D, Slora E, Hussey M, Dowshen SA, et al. Secondary sexual characteristics in boys: data from the Pediatric Research in Office Settings Network. *Pediatrics.* 2012; 130: e1058-e1068.
- Eckert-Lind C, Busch AS, Petersen JH, Biro FM, Butler G, Bräuner EV, et al. Worldwide secular trends in age at pubertal onset assessed by breast development among girls: A systematic review and meta-analysis. *JAMA Pediatr.* 2020; 174: e195881.
- Li N, Ying GG, Hong H, Tsang EPK, Deng WJ. Plasticizer contamination in the urine and hair of preschool children, airborne particles in kindergartens, and drinking water in Hong Kong. *Environ Pollut.* 2021; 271: 116394.

21. Greenspan LC, Lee MM. Endocrine disrupters and pubertal timing. *Curr Opin Endocrinol Diabetes Obes.* 2018; 25: 49-54.
22. Papadimitriou A, Papadimitriou DT. Endocrine-disrupting chemicals and early puberty in girls. *Children (Basel).* 2021; 8: 492.
23. Ng H, Perkins R, Tong W, Hong H. Versatility or promiscuity: The estrogen receptors, control of ligand selectivity and an update on subtype selective ligands. *Int. J. Environ. Res. Public Health.* 2014; 11: 8709-8742.
24. Sakkiah S, Wang T, Zou W, Wang Y, Pan B, Tong W, et al. Endocrine disrupting chemicals mediated through binding androgen receptor are associated with diabetes mellitus. *Int J Environ Res Public Health.* 2017;15: 25.
25. Hewlett M, Chow E, Aschengrau A, Mahalingaiah S. Prenatal exposure to endocrine disruptors: a developmental etiology for polycystic ovary syndrome. *Reprod Sci.* 2017; 24: 19-27.
26. James-Todd T, Connolly L, Preston EV, Quinn MR, Plotan M, Xie Y, et al. Hormonal activity in commonly used Black hair care products: evaluating hormone disruption as a plausible contribution to health disparities. *J Expo Sci Environ Epidemiol.* 2021; 31: 476-486.
27. Grymowicz M, Rudnicka E, Podfigurna A, Napierala P, Smolarczyk R, Smolarczyk K, et al. Hormonal effects on hair follicles. *Int J Mol Sci.* 2020; 21: 5342.
28. Redler S, Messenger AG, Betz RC. Genetics and other factors in the aetiology of female pattern hair loss. *Exp Dermatol.* 2017; 26: 510-517.
29. Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. *Br J Dermatol.* 1992; 127: 239-246.
30. Magro CM, Rossi A, Poe J, Manhas-Bhutani S, Sadick N. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. *J Drugs Dermatol.* 2011; 10: 1404-11.
31. Mahé YF, Buan B, Billoni N, Loussouarn G, Michelet JF, Gautier B, et al. Pro-inflammatory cytokine cascade in human plucked hair. *Skin Pharmacol.* 1996; 9: 366-375.
32. Ramos PM, Brianezi G, Martins AC, da Silva MG, Marques ME, Miot HA. Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation. *Int J Cosmet Sci.* 2016; 38: 651-654.
33. Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. *Br J Dermatol.* 2006; 155: 926-930.
34. Kligman AM. The comparative histopathology of male-pattern baldness and senescent baldness. *Clin Dermatol.* 1988; 6: 108-118.
35. Barber TM, Kabisch S, Pfeiffer AFH, Weickert MO. The health benefits of dietary fibre. *Nutrients.* 2020; 12: 3209.
36. González Olmo BM, Butler MJ, Barrientos RM. Evolution of the human diet and its impact on gut microbiota, immune responses, and brain health. *Nutrients.* 2021; 13: 196.
37. Martínez Leo EE, Peñafiel AM, Hernández Escalante VM, Cabrera Araujo ZM. Ultra-processed diet, systemic oxidative stress, and breach of immunologic tolerance. *Nutrition.* 2021.
38. Bujtor M, Turner AI, Torres SJ, Esteban-Gonzalo L, Pariante CM, Borsini A. Associations of dietary intake on biological markers of inflammation in children and adolescents: a systematic review. *Nutrients.* 2021; 13: 356.
39. Pearce EN. Is iodine deficiency reemerging in the United states?. *AACE Clinical Case Reports.* 2015; 1: e81-82.
40. Panth P, Guerin G, DiMarco NM. A review of iodine status of women of reproductive age in the USA. *Biol Trace Elem Res.* 2019; 188: 208-220.
41. Ortega RM, Rodríguez-Rodríguez E, Aparicio A, Jiménez-Ortega AI, Palmeros C, Perea JM. Young children with excess of weight show an impaired selenium status. *Int J Vitam Nutr Res.* 2012; 82: 121-129.
42. Fontenelle LC, Cardoso de Araújo DS, da Cunha Soares T, Climaco Cruz KJ, Henriques GS, Marreiro DDN. Nutritional status of selenium in overweight and obesity: A systematic review and meta-analysis. *Clin Nutr.* 2022; 41: 862-884.
43. Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, et al. Female pattern hair loss and androgen excess: A report from the multidisciplinary androgen excess and PCOS Committee. *J Clin Endocrinol Metab.* 2019; 104: 2875-2891.
44. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). *Clin Endocrinol (Oxf).* 2008; 68: 311-316.
45. Razvi S, Korevaar TIM, Taylor P. Trends, determinants, and associations of treated hypothyroidism in the United kingdom, 2005-2014. *Thyroid.* 2019; 29: 174-182.
46. Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía-Eisman A, Giron-Prieto MS, Naranjo-Sintes R. A comparative study of dyslipidaemia in men and woman with androgenic alopecia. *Acta Derm Venereol.* 2010; 90: 485-487.
47. Coogan PF, Bethea TN, Cozier YC, Bertrand KA, Palmer JR, Rosenberg L, et al. Association of type 2 diabetes with central-scalp hair loss in a large cohort study of African American women. *Int J Womens Dermatol.* 2019; 5: 261-266.
48. Bakry OA, Shoeib MA, El Shafiee MK, Hassan A. Androgenetic alopecia, metabolic syndrome, and insulin resistance: Is there any association? A case-control study. *Indian Dermatol Online J.* 2014; 5: 276-281.
49. Agamia NF, Abou Youssif T, El-Hadidy A, El-Abd A. Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship?. *Arab J Urol.* 2016; 14: 157-162.
50. Su LH, Chen LS, Lin SC, Chen HH. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. *JAMA Dermatol.* 2013; 149: 601-606.
51. Hirsso P, Laakso M, Matilainen V, Hiltunen L, Rajala U, Jokelainen J. Association of insulin resistance linked diseases and hair loss in elderly men. Finnish population-based study. *Cent Eur J Public Health.* 2006; 14: 78-81.
52. Koyama T, Kobayashi K, Wakisaka N, Hirayama N, Konishi S, Hama T, et al. Eleven pairs of Japanese male twins suggest the role of epigenetic differences in androgenetic alopecia. *Eur J Dermatol.* 2013; 23: 113-115.
53. Lai CH, Chu NF, Chang CW, Wang SL, Yang HC, Chu CM, et al. Androgenic alopecia is associated with less dietary soy, lower [corrected] blood vanadium and rs1160312 1 polymorphism in Taiwanese communities. *PLoS One.* 2013; 8: e79789.
54. Millar SE. Committing to a hairy fate: epigenetic regulation of hair follicle stem cells. *Cell Stem Cell.* 2011; 9: 183-184.
55. Lien WH, Guo X, Polak L, Lawton LN, Young RA, Zheng D, et al. Genome-wide maps of histone modifications unwind in vivo chromatin states of the hair follicle lineage. *Cell Stem Cell.* 2011; 9: 219-232.
56. Lee J, Kang S, Lilja KC, Colletier KJ, Scheitz CJ, Zhang YV, et al. Signalling couples hair follicle stem cell quiescence with reduced histone H3 K4/K9/K27me3 for proper tissue homeostasis. *Nat Commun.* 2016; 7: 11278.
57. Kocic H, Damiani G, Stamenkovic B, Tirant M, Jovic A, Todorovic D, et al. Dietary compounds as potential modulators of microRNA expression in psoriasis. *Ther Adv Chronic Dis.* 2019.

58. Quinn M, Jordan H, Lacy-Nichols J. Upstream and downstream explanations of the harms of ultra-processed foods in national dietary guidelines. *Public Health Nutr.* 2021; 24: 5426-5435.
59. Hosking AM, Juhasz M, Atanaskova Mesinkovska N. Complementary and alternative treatments for alopecia: A comprehensive review. *Skin Appendage Disord.* 2019; 5: 72-89.
60. Zgonc Škulj A, Poljšak N, Kočevar Glavač N, Kreft S. Herbal preparations for the treatment of hair loss. *Arch Dermatol Res.* 2020; 312: 395-406.
61. Kupczyk M, Kuna P. Targeting the PGD2/CRT2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. *Drugs.* 2017; 77(12):1281-1294.
62. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. *Sci Transl Med.* 2012; 4: 126ra134.
63. Ratner P, Andrews CP, Hampel FC, Martin B, Mohar DE, Bourrelly D, et al. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies. *Allergy Asthma Clin Immunol.* 2017; 4: 18.
64. DuBois J, Bruce S, Stewart D, Kempers S, Harutunian C, Boodhoo T, et al. Setipiprant for androgenetic alopecia in males: results from a randomized, double-blind, placebo-controlled phase 2a trial. *Clin Cosmet Investig Dermatol.* 2021; 15: 1507-1517.
65. Sakib SA, Tareq AM, Islam A, Rakib A, Islam MN, Uddin MA, et al. Anti-inflammatory, thrombolytic and hair-growth promoting activity of the n-hexane fraction of the methanol extract of lea indica leaves. *Plants (Basel).* 2021; 10: 1081.
66. Clayton P, Venkatesh R, Bogoda N, Subah S. *Ageratum Conyzoides* L. Extract inhibits 5 α -reductase gene expression and prostaglandin d2 release in human hair dermal papilla cells and improves symptoms of hair loss in otherwise healthy males and females in an open label pilot study. *J Cosmetol Trichol* 2021, 7(1).
67. Clayton P, Venkatesh R, Mentha S, Bogoda N, Subah S, Rao A, et al. Efficacy of a topical application of *ageratum conyzoides* on increasing hair growth and in males and females: a randomized double-blind placebo-controlled study. *Trichol Cosmetol Open J.* 2022; 5: 10-15.
68. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet.* 2019; 393: 434-445.
69. De Pessemier B, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut-skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. *Microorganisms.* 2021; 9: 353.
70. Williams R. Benefit and mischief from commensal bacteria. *J. Clin. Pathol.* 1973; 26: 811.
71. Hayashi A, Mikami Y, Miyamoto K, Kamada N, Sato T, Mizuno S, et al. Intestinal dysbiosis and biotin deprivation induce alopecia through overgrowth of *lactobacillus murinus* in mice. *Cell Rep.* 2017; 20: 1513-1524.
72. Biotin deficiency. In: *haschek and rousseaux's handbook of toxicologic pathology (Third Edition), 2013*
73. Belda E, Voland L, Tremaroli V, Falony G, Adriouch S, Assmann KE, et al. Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism. *Gut.* 2022.
74. McLoughlin RF, Berthon BS, Jensen ME, Baines KJ, Wood LG. Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. *Am J Clin Nutr.* 2017; 106: 930-945.
75. Thaiss CA, Levy M, Suez J, Elinav E. The interplay between the innate immune system and the microbiota. *Curr. Opin. Immunol.* 2014; 26: 41-48.
76. Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff B.J, et al. Maintenance of hair follicle immune privilege is linked to prevention of nk cell attack. *J. Investig. Dermatol.* 2008; 128: 1196-1206.
77. Lousada MB, Lachnit T, Edelkamp J, Rouillé T, Ajdic D, Uchida Y, et al. Exploring the human hair follicle microbiome. *Br J Dermatol.* 2021; 184: 802-815.
78. Flowers L, Grice EA. The Skin Microbiota: Balancing Risk and Reward. *Cell Host Microbe.* 2020; 28: 190-200.
79. Constantinou A, Kanti V, Polak-Witka K, Blume-Peytavi U, Spyrou GM, Vogt A. The potential relevance of the microbiome to hair physiology and regeneration: the emerging role of metagenomics. *Biomedicine.* 2021; 9: 236.
80. Polak-Witka K, Rudnicka L, Blume-Peytavi U, Vogt A. The role of the microbiome in scalp hair follicle biology and disease. *Exp. Dermatol.* 2020; 29: 286-294.
81. Sakamoto K, Jin SP, Goel S, Jo JH, Voisin B, Kim D, et al. Disruption of the endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate lymphoid cell-mediated hair follicle destruction. *Immunity.* 2021; 54: 2321-2337.e10.
82. Juhasz M, Chen S, Khosrovi-Eghbal A, Ekelem C, Landaverde Y, Baldi P, et al. Characterizing the skin and gut microbiome of alopecia areata patients. *SKIN J. Cutan. Med.* 2020; 4: 23-30.
83. Sadick NS, Callender VD, Kircik LH, Kogan S. New insight into the pathophysiology of hair loss trigger a paradigm shift in the treatment approach. *J Drugs Dermatol.* 2017; 16: s135-s140.
84. Heymann WR. The inflammatory component of androgenetic alopecia. *J Am Acad Dermatol.* 2022; 86: 301-302.
85. Plante J, Valdebran M, Forcucci J, Lucas O, Elston D. Perifollicular inflammation and follicular spongiosis in androgenetic alopecia. *J Am Acad Dermatol.* 2022; 86: 437-438.
86. Farris PK, Rogers N, McMichael A, Kogan S. A novel multi-targeting approach to treating hair loss, using standardized nutraceuticals. *J Drugs Dermatol.* 2017; 16: s141-s148.
87. Rebello D, Wang E, Yen E, Lio PA, Kelly CR. Hair growth in two alopecia patients after fecal microbiota transplant. *ACG Case Rep J.* 2017; 4: e107.
88. Huang J, Ran Y, Pradhan S, Yan W, Dai Y. Investigation on microecology of hair root fungi in androgenetic alopecia patients. *Mycopathologia.* 2019; 184: 505-515.
89. Pinto D, Sorbellini E, Marzani B, Rucco M, Giuliani G, Rinaldi F. Scalp bacterial shift in Alopecia areata. *PLoS ONE.* 2019; 14: e0215206.
90. Pessemier B de, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut-Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. *Microorganisms.* 2021; 9: 353.
91. Lee SY, Lee E, Park YM, Hong SJ. Microbiome in the gut-skin axis in atopic dermatitis. *Allergy Asthma Immunol Res.* 2018; 10: 354-362.
92. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. *Diabetes Metab.* 2012; 38: 183-191.
93. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. *Curr Diabetes Rev.* 2020; 16: 442-449.
94. Yosipovitch G, Tur E, Cohen O, Rusecki Y. Skin surface pH in intertriginous areas in NIDDM patients. Possible correlation to candidal intertrigo. *Diabetes Care.* 1993; 16: 560-563.

95. Robertson MD. Probiotics and type 2 diabetes: targeting the gut microbiota for improved glycaemic control? *Practical Diabetes* 2020; 37: 133-137.
96. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet*. 2018; 391: 541-551.
97. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol*. 2019; 7: 344-355.
98. Taheri S, Zaghoul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2020; 8: 477-489.
99. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002; 346: 393-403.
100. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr*. 2015; 102: 780-90.
101. Tay J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Noakes M, Buckley JD, et al. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial. *Diabetes Obes Metab*. 2018; 20: 858-871.
102. Chen CY, Huang WS, Chen HC, Chang CH, Lee LT, Chen HS, et al. Effect of a 90 g/day low-carbohydrate diet on glycaemic control, small, dense low-density lipoprotein and carotid intima-media thickness in type 2 diabetic patients: An 18-month randomised controlled trial. *PLoS One*. 2020; 15: e0240158.
103. Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E, et al. A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. *Diabetologia*. 2019; 62: 2066-2078.
104. Juul F, Parekh N, Martinez-Steele E, Monteiro CA, Chang VW. Ultra-processed food consumption among US adults from 2001 to 2018. *Am J Clin Nutr*. 2022; 115: 211-221.
105. Koiwai K, Takemi Y, Hayashi F, Ogata H, Matsumoto S, Ozawa K, et al. Consumption of ultra-processed foods decreases the quality of the overall diet of middle-aged Japanese adults. *Public Health Nutr*. 2019; 22: 2999-3008.
106. Marino M, Puppo F, Del Bo', C, Vinelli V, Riso P, Porrini M, et al. A systematic review of worldwide consumption of ultra-processed foods: findings and criticisms. *Nutrients* 2021, 13, 2778.
107. Martínez Leo EE, Segura Campos MR. Effect of ultra-processed diet on gut microbiota and thus its role in neurodegenerative diseases. *Nutrition*. 2020; 71: 110609.
108. Weinstein G, Vered S, Ivancovsky-Wajcman D, Springer RR, Heymann A, Zelber-Sagi S, et al. Consumption of ultra-processed food and cognitive decline among older adults with type-2 diabetes. *J Gerontol A Biol Sci Med Sci*. 2022; glac070.
109. Fiolet T, Srour B, Sellem L, Kesse-Guyot E, Allès B, Méjean C, et al. Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort. *BMJ*. 2018; 360: k322.
110. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2021; 18: 223-238.
111. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. 2018; 15: 11-20.
112. Global panel on agriculture and food systems for nutrition. *Food systems and diets: facing the challenges of the 21st century*. 2016.
113. Shivappa N, Stack SE, Hurley TG, Hussey JR, Hébert JR. Designing and developing a literature-delivered, population-based dietary inflammatory index. *Public Health Nutr*. 2014; 17: 1689-96.
114. Monteiro CA, Cannon G, Maubarac JC, Levy RB, Louzada MLC, Jaime PC. The un decade of nutrition, the nova food classification and the trouble with ultra-processing. *Public Health Nutr*. 2018; 21: 5-17.
115. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. *Lancet*. 2015; 385: 117-171.
116. Skoracka K, Eder P, Łykowska-Szuber L, Dobrowolska A, Krela-Kaźmierczak I. Diet and nutritional factors in male (in)fertility-underestimated factors. *J Clin Med*. 2020; 9: 1400.
117. Panth N, Gavarkovs A, Tamez M, Mattei J. The influence of diet on fertility and the implications for public health nutrition in the united states. *Front Public Health*. 2018; 31: 211.
118. Wolf R, Schönfelder G, Paul M, Blume-Peytavi U. Nitric oxide in the human hair follicle: Constitutive and dihydrotestosterone-induced nitric oxide synthase expression and NO production in dermal papilla cells. *J. Mol. Med*. 2003; 81: 110-117.
119. Uno H. The stumptailed macaque as a model for baldness: effects of minoxidil. *Int J Cosmet Sci*. 1986; 8: 63-71.
120. Huneke RB, Foltz CJ, VandeWoude S, Mandress TD, Garman RH. Characterization of dermatologic changes in geriatric rhesus macaques. *J Med Primatol* 1996; 25: 404-413.
121. Horenstein VD-P, Williams LE, Brady AR, Abee CR, Horenstein MG. Age-related diffuse chronic telogen effluvium-type alopecia in female squirrel monkeys (*Saimiri boliviensis boliviensis*). *Comp Med* 2005; 55: 169-174.
122. Pirastu N, Joshi PK, de Vries PS, Cornelis MC, McKeigue PM, Keum N, et al. GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk. *Nat Commun*. 2017; 8: 1584.
123. Pham CT, Romero K, Almohanna HM, Griggs J, Ahmed A, Tosti A. The role of diet as an adjuvant treatment in scarring and nonscarring alopecia. *Skin Appendage Disord*. 2020; 6: 88-96.